Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 29

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 29
---
 foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. These provisions may discourage stockholders from bringing a lawsuit against our directors in the future for any breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. We believe that these provisions, the indemnification agreements and the insurance are necessary to attract and retain talented and experienced directors and officers. At present, there is no pending litigation or proceeding involving any of our directors, officers or employees in which indemnification will be required or permitted. We are not aware of any threatened litigation or proceeding that might result in a claim for such indemnification. 18

EXECUTIVE OFFICERS OF SUPERNUS The following table sets forth the names and ages of our executive officers as of the date of this Proxy Statement.

| Name                      | ​ | ​ | Age |   |    |   | ​ | ​ | Position(s)                                                                                     | ​ |
| Jack A. Khattar           | ​ | ​ | ​   | ​ | 63 | ​ | ​ | ​ | President, Chief Executive Officer & Secretary, Director                                        | ​ |
| Timothy C. Dec            | ​ | ​ | ​   | ​ | 66 | ​ | ​ | ​ | Senior Vice President, Chief Financial Officer                                                  | ​ |
| Padmanabh P. Bhatt, Ph.D. | ​ | ​ | ​   | ​ | 67 | ​ | ​ | ​ | Senior Vice President of Intellectual Property, Chief Scientific Officer                        | ​ |
| Frank Mottola             | ​ | ​ | ​   | ​ | 53 | ​ | ​ | ​ | Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs | ​ |
| Jonathan Rubin, M.D.      | ​ | ​ | ​   | ​ | 63 | ​ | ​ | ​ | Senior Vice President, Chief Medical Officer, Research and Development                          | ​ |

Jack A. Khattar . See “Election of Directors.” Timothy C. Dec has more than 35 years of experience in accounting and finance across many industries, including